These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24926510)

  • 21. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapentadol (Palexia) for moderate to severe acute pain.
    Drug Ther Bull; 2012 Mar; 50(3):30-3. PubMed ID: 22419754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
    Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
    J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources.
    Cepeda MS; Sutton A; Weinstein R; Kim M
    Clin J Pain; 2012 Jan; 28(1):8-13. PubMed ID: 21646907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dual-opioid therapy in acute pain.
    Webster L
    Pain Med; 2012 Mar; 13 Suppl 1():S12-20. PubMed ID: 22420602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of tapentadol in chronic severe pain.
    Riemsma R; Forbes C; Harker J; Worthy G; Misso K; Schäfer M; Kleijnen J; Stürzebecher S
    Curr Med Res Opin; 2011 Oct; 27(10):1907-30. PubMed ID: 21905968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
    Kwong WJ; Ozer-Stillman I; Miller JD; Haber NA; Russell MW; Kavanagh S
    Clin Ther; 2010 Sep; 32(10):1768-81. PubMed ID: 21194601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment.
    Hofmann JF; Lal A; Steffens M; Boettger R
    J Opioid Manag; 2016; 12(5):323-331. PubMed ID: 27844472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tapentadol immediate-release for acute pain.
    Hartrick CT
    Expert Rev Neurother; 2010 Jun; 10(6):861-9. PubMed ID: 20518601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.
    Kavanagh S; Kwong WJ; Hammond GC; Nelson W; Upmalis D; Yang M
    Pain Med; 2012 Sep; 13(9):1110-20. PubMed ID: 22845494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.